Newly on Gate2Biotech
TiGenix provides ChondroCelect update
10.6.2013 | Newly on Gate2Biotech
Leuven (BELGIUM) - June 7, 2013 - TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, today provided an update on the commercial prospects of ChondroCelect, its characterized chondrocyte implantation for symptomatic cartilage lesions in the knee.
First baby born in the UK using Early Embryo Viability Assessment (EevaTM) test
5.6.2013 | Newly on Gate2Biotech
Menlo Park, CA, 5 June 2013 - Auxogyn, Inc. announced today the birth of one of the first babies to be born after embryologists used the Early Embryo Viability Assessment (EevaTM). Auxogyn at the forefront of revolutionizing IVF treatment.
Nanobiotix\'s NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma
3.6.2013 | Newly on Gate2Biotech
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its lead nanoparticle-based product, NBTXR3, in patients with Soft Tissue Sarcoma (STS).
European and US Cellulase Patents granted to Direvo Industrial Biotechnology GmbH
31.5.2013 | Newly on Gate2Biotech
Cologne, Germany, May 21, 2013. Direvo Industrial Biotechnology GmbH (Direvo), an expert in enzyme development and optimization from Cologne, announced today the granting of U.S. and European Patents covering novel cellulase enzymes.
Auxogyn Selected to Present at European BioEquity Conference in Stockholm
29.5.2013 | Newly on Gate2Biotech
Menlo Park, CA – May 22 2013 – Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, announced that Lissa Goldenstein, CEO and President of Auxogyn will be a featured speaker at the 14th European BioEquity...
MIT Venture Competition
28.5.2013 | Newly on Gate2Biotech
The MIT/European "Building Global Innovators" program (BGI) (http://mitportugal-iei.org/) was originally established as a partnership between MIT and the government of Portugal (with the University Institute of Lisbon being the Portuguese administrator). The program is primarily funded by the Portuguese government and some private...
Central and Eastern Europe - rising star of biotech market
27.5.2013 | Newly on Gate2Biotech
BioForum 2013 finished successfully. Just finished event could we sum up in easy way: Central and Eastern Europe Life Science sector grows dynamically and plays increasingly role on global biotech market which is estimated more than 400 billion euro. BioForum 2013 strengthens this role throughout building cooperation between companies and...
Polish-Hungarian cooperation as a big chance for creating new emerging bioregion: Central and Eastern Europe
16.5.2013 | Newly on Gate2Biotech
On 22 May 2013 there will be signed a historic agreement concerning cooperation between Polish Biotech Association (PBA) and the Hungarian Biotechnology Association (HBA - Magyar Biotechnológiai Szövetség). This will be an important step in the development process of biotechnology and life science sector as a whole, not only in Poland and Hungary,...
Biosimilars – Central and Eastern Europe perspective
14.5.2013 | Newly on Gate2Biotech
It is kind of truism to say that biotechnological products are the future of medicine. Especially, if their natural property to be recognized by human body as a natural and self-produced protein combating with particular disease is taken into consideration. Biosimilar market is estimated to be worth USD 2-3 bln by 2015, and up to USD 20 bn by...
Personalized medicine – a key to heal the cancer?
10.5.2013 | Newly on Gate2Biotech
Personalized medicine more and more often means not only individual approach of physicians. It is more than deep knowledge of case history and the treatment received by patients so far. Personalized medicine is a key to understand the illness not in only in perspective of human race, but in elementary view of every human being. This key...
